Rhythm raises $25M in Series B financing for diabetes and obesity

Thursday, June 14, 2012 09:14 AM

Rhythm, a biotech based in Boston, Mass., has raised $25 million in a Series B financing round, bringing the total capital raised to $65 million.

Rhythm will use the proceeds to continue advancing its small-peptide therapeutics for metabolic diseases through phase II clinical trials. RM-131 is a ghrelin agonist currently in phase II study for the treatment of diabetic gastroparesis. RM-493, an agonist of the melanocortin 4 receptor (MC4R), is currently in phase II trials for the treatment of obesity and diabetes.

"We have made great progress since we started both development programs in 2010, and this could only have been achieved with a strong and dedicated investor syndicate," said Bart Henderson, founder and president of Rhythm. "These programs have great potential for addressing major unmet needs in diabetes, obesity and gastrointestinal functional disorders, and this financing supports a broad and thorough phase II development program for both drugs."

All existing investors participated in the round — MPM Capital, New Enterprise Associates and Third Rock Ventures — as well as new investor, Ipsen.

"We see the potential for transforming the treatment of diabetes and other metabolic diseases with molecules that activate the ghrelin and MC4R pathways with high potency and specificity,” said Lou Tartaglia, PhD, partner at Third Rock Ventures. “We are pleased to invest in Rhythm and to be working with a great management team as it moves this exciting portfolio of peptides forward."

In connection with the financing, Vaughn Kailian, managing director of MPM Capital, was added to Rhythm's board of directors. He joins board members Tartaglia; Keith Gottesdiener, MD, CEO of Rhythm; Ed Mathers, a partner at NEA; and Christian de la Tour, chairman of Ipsen U.K. Companies.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs